|Day Low/High||283.36 / 288.11|
|52 Wk Low/High||223.02 / 338.51|
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2017 RBC Capital Markets Global Healthcare Conference.
Jim Cramer compares Allergan's growth to other pharma stocks.
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 6 th Annual Global Healthcare Conference.
Here are Tuesday's top research calls, including upgrades for Biogen and Caterpillar, and increased price targets for Apple and Micron.
The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
The biotech disclosed subpoenas in a regulatory filing.
The Fed is simply not a market catalyst this time.
Biogen Inc. (NASDAQ: BIIB) today announced the completion on February 1, 2017 of the separation of its global hemophilia business.
Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.
The sale of the $800M stake to Temasek comes as the Google parent scales back some of its other big bets.
The Dow Jones Industrial Average scores a record close for its second day in a row, benefiting from a small bump that cemented its position above 20,000.
The Dow Jones Industrial Average is on track to squeeze out another record close, its second in a row, in a mixed session.
For 2017 to work, Biogen needs a successful commercial launch of Spinraza, the newly approved treatment for spinal muscular atrophy, a rare and fatal disease that strikes kids.
Stocks hold mixed on Thursday as markets run out of steam to push a record-breaking rally into day two.
Stock futures turn mixed on Thursday as investors take pause after Wednesday's history-making rally.
McKesson, Bristol-Myers and Varian were having a busy morning.
Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2016 financial results, including: Full year total revenues of $11.
There are several reasons why Celgene should buy Biogen.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.
Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.
Please note: the start time of the webcast has moved to 8:00 am ET.
Siemens Healthineers and Biogen have announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity...
Biogen Inc. (NASDAQ: BIIB) today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma's shareholders and other customary...
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.